Related references
Note: Only part of the references are listed.Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease
Antonio Petrarca et al.
BLOOD (2010)
Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: Targeting the infectious trigger, the autoimmune response, or both?
Salvatore De Vita et al.
AUTOIMMUNITY REVIEWS (2008)
Efficacy of low-dose rituximab for mixed cryoglobulinemia
Marcella Visentini et al.
CLINICAL IMMUNOLOGY (2007)
Hepatitis C virus-related lymphoproliferative disorders: An overview
Anna Linda Zignego et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Analysis of hepatitis C virus hypervariable region 1 sequence from cryoglobulinemic patients and associated controls
Gabriella Bianchettin et al.
JOURNAL OF VIROLOGY (2007)
Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders
AJ Novak et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia
TS Lin et al.
BLOOD (2005)
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease
E Louis et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Rituximab-dependent cytotoxicity by natural killer cells:: Influence of FCGR3A polymorphism on the concentration-effect relationship
S Dall'Ozzo et al.
CANCER RESEARCH (2004)
Fcγ receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus -: Contribution of FCGR2B to genetic susceptibility
C Kyogoku et al.
ARTHRITIS AND RHEUMATISM (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Share Paper
